Epco, Zanu, Ritux for R/R FL or MZL

This study is testing a three-drug combination — epcoritamab, zanubrutinib, and rituximab — for patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back or is no longer responding to prior treatment. These drugs work together to target cancer cells using different mechanisms. **You may be eligible if...** - You are 18 or older with confirmed follicular lymphoma (grade 1–3A) or marginal zone lymphoma (any subtype) - You have received at least one prior treatment that included a CD20-targeting drug (like rituximab) - You have measurable disease visible on imaging - Your disease meets certain criteria indicating treatment is needed (symptoms, organ problems, large tumors, or certain blood count changes) **You may NOT be eligible if...** - Your lymphoma has transformed into a more aggressive (higher-grade) type - You have active hepatitis B or C, or HIV not well controlled - You have had a prior stem cell transplant within 6 months - You are pregnant or breastfeeding - You have poor overall health status Talk to your doctor to see if this trial is right for you.